Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mechanistic Insights into the Role of Artificial Intelligence and Machine Learning in the Diagnosis and Management of Multiple Sclerosis.

Pathophysiology : the official journal of the International Society for Pathophysiology·2026
Same author

Is There a Unified Etiology of Hypoplastic Left Heart Syndrome? Evaluating Genetic, Structural, and Hemodynamic Models of Disease Initiation.

Pathophysiology : the official journal of the International Society for Pathophysiology·2026
Same author

Clinical Phenotypes of Obstructive Sleep Apnea: A Decade of Evidence Toward Personalized Management.

Pathophysiology : the official journal of the International Society for Pathophysiology·2026
Same author

From rodents to algorithms: The rise of virtual animals in drug development and neuroscience.

Clinical neurology and neurosurgery·2025
Same author

Neurogranin-MYH9 interaction regulates cytoskeletal remodeling in cerebral vasculature.

Fluids and barriers of the CNS·2025
Same author

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices.

Journal of visualized experiments : JoVE·2024

Related Experiment Video

Updated: Jun 16, 2026

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

Alemtuzumab and multiple sclerosis: therapeutic application.

Alireza Minagar1, J Steven Alexander, Mohammad Ali Sahraian

  • 1Louisiana State University Health Sciences Center, Department of Neurology, 1501 Kings Highway, Shreveport, LA 71130, USA. aminag@lsuhsc.edu

Expert Opinion on Biological Therapy
|January 26, 2010
PubMed
Summary

Alemtuzumab, a monoclonal antibody, shows promise for treating multiple sclerosis (MS) by depleting T and B lymphocytes. This biologic agent offers a new option for patients unresponsive to traditional therapies.

More Related Videos

Imaging CD19+ B Cells in an Experimental Autoimmune Encephalomyelitis Mouse Model using Positron Emission Tomography
09:41

Imaging CD19+ B Cells in an Experimental Autoimmune Encephalomyelitis Mouse Model using Positron Emission Tomography

Published on: January 20, 2023

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube (SWCNT)-delivered MALAT1 Antisense Oligos
07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube (SWCNT)-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

Related Experiment Videos

Last Updated: Jun 16, 2026

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

Imaging CD19+ B Cells in an Experimental Autoimmune Encephalomyelitis Mouse Model using Positron Emission Tomography
09:41

Imaging CD19+ B Cells in an Experimental Autoimmune Encephalomyelitis Mouse Model using Positron Emission Tomography

Published on: January 20, 2023

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube (SWCNT)-delivered MALAT1 Antisense Oligos
07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube (SWCNT)-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

Area of Science:

  • Immunology
  • Neurology
  • Pharmacology

Background:

  • Multiple sclerosis (MS) lacks a definitive cure, with current treatments offering limited efficacy and tolerability.
  • Existing immunomodulatory and immunosuppressive therapies for MS have significant drawbacks, including partial effectiveness and serious side effects.
  • Monoclonal antibodies represent a promising class of biologic agents for immune-mediated disorders like MS.

Purpose of the Study:

  • To review the mechanisms of action of alemtuzumab.
  • To present the results of Phase II clinical trials of alemtuzumab in multiple sclerosis.
  • To discuss the potential of alemtuzumab as a treatment for MS.

Main Methods:

  • Review of alemtuzumab's mechanism of action.
  • Analysis of Phase II clinical trial data in multiple sclerosis patients.
  • Discussion of adverse effects observed in clinical trials.

Main Results:

  • Alemtuzumab is a humanized monoclonal antibody targeting CD52 on lymphocytes and other immune cells.
  • Intravenous administration of alemtuzumab leads to prolonged depletion of T and B lymphocytes.
  • Adverse events such as thyroid disorders and idiopathic thrombocytopenic purpura were observed in MS patients.

Conclusions:

  • Alemtuzumab demonstrates significant promise as a treatment option for multiple sclerosis, particularly for patients refractory to other therapies.
  • Its unique mechanism of action and profound impact on MS disease activity advance understanding of MS pathogenesis.
  • Alemtuzumab offers a novel therapeutic strategy for managing multiple sclerosis.